Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Explains How Big A Hit It May Take From Biosimilars, Pricing Pressures

Jan 30 2019

• By Mandy Jackson

Stock exchange graph screen electronic company corporate index display profit economic global graphic loss succes

Related Content

Evenity Likely Headed For Approval With Amgen's Proposed Indication, But Postmarketing Requirements Remain Unclear

Jan 17 2019

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

Amgen's Aimovig Riding High With Strong Prescriber, Payer Acceptance

Oct 31 2018

Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive

Nov 15 2018

Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta

Nov 10 2018

Q4 Earnings Preview: Pfizer, Amgen, Allergan, Biogen And Novartis

Jan 26 2019

Related Companies

Amgen, Inc.

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Novartis AG

Johnson & Johnson

Additional Topics

Sales & Earnings Biosimilars Launches Business Strategies Companies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.